학술논문
Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider.
Document Type
Article
Author
Source
Subject
*THERAPEUTIC use of monoclonal antibodies
*THERAPEUTIC use of antineoplastic agents
*CANCER patient psychology
*ACADEMIC medical centers
*MOTIVATION (Psychology)
*FUNCTIONAL status
*PATIENT satisfaction
*HEALTH outcome assessment
*PATIENTS' attitudes
*QUALITY of life
*QUESTIONNAIRES
*RESEARCH funding
*EMOTIONS
*CUTANEOUS T-cell lymphoma
*LONGITUDINAL method
*SYMPTOMS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Patients with erythrodermic cutaneous T-cell lymphoma often experience severe symptoms. This study provides an insight into the impact of the disease, mogamulizumab treatment, and essential patient-reported outcomes. The data on patients' expectation, quality of life, and treatment satisfaction can especially be used in the counseling of future patients. Background: Erythrodermic cutaneous T-cell lymphoma (E-CTCL) is associated with a poor prognosis and severe symptoms. Objective: To establish insights into the quality of life (QoL), expectations, and treatment satisfaction of E-CTCL patients receiving mogamulizumab. Methods: Outcomes of this prospective cohort study conducted between September 2020 and August 2021 at the Leiden University Medical Center included the dermatology-specific QoL (Skindex-29), health-related QoL (RAND-12), degree of itch, pain, and fatigue (Visual Analogue Scale), patient's expectations, and treatment satisfaction (Client Satisfaction Questionnaire-8 (CSQ-8)), measured at baseline and after six months. Results: 13 patients with E-CTCL were included. Most patients anticipated a positive treatment effect on symptoms. Five patients (46%) improved one or more clinical categories regarding the symptoms domain, six (55%) regarding emotions, four (36%) regarding functioning, and four (36%) regarding the overall Skindex-29 score compared to baseline. The Mental Component Score clinically improved from 31 (IQR 29–51) at baseline to 38 (IQR 25–51). The median VAS itch improved significantly from baseline (8 (IQR 7–10) vs. 3 (IQR 1–8), p = 0.024). Most patients (n = 7) were "very satisfied" with their treatment. Limitations: There was a limited number of patients due to the rarity of the disease. Conclusion: In general, mogamulizumab has a favorable effect on biochemical- and dermatology-specific QoL and physical functioning in some patients, with high treatment satisfaction. Itch especially improved over time in most patients. The treatment satisfaction was generally high. Mogamulizumab seems to be an effective treatment that improves the QoL in patients with E-CTCL. [ABSTRACT FROM AUTHOR]